A letter from Robert Pacifici PhD, Chief Scientific Officer, CHDI, to our collaborators about working practices during the pandemic

Dear CHDI Collaborator:

The current coronavirus pandemic is affecting all of us in very unwelcomed and uncertain ways. First and foremost, I’m reaching out to you on behalf of all of us at CHDI to express our sincere wishes that you, your colleagues and institution, and your families are coping with the circumstances as best you can. Read more…

Charles River Laboratories and CHDI Foundation extend Huntington’s disease collaboration

WILMINGTON, Mass. – April 9, 2019 — Charles River Laboratories International, Inc. (NYSE: CRL) and CHDI Foundation today announced a five-year extension of their ongoing collaboration. The organizations began working together in 2005 on drug discovery and development for Huntington’s disease (HD), a genetic neurological disease that causes the progressive dysfunction of nerve cells in the brain. The extension will allow more flexible activity across the different Charles River platforms and entail greater integration into CHDI’s programs. Read more…